"We chose outcomes that were important to patients and clinicians alike," DCRI's @schuyler_jones says while sharing additional insights on @ADAPTABLEstudy during an #ACC21 deep dive.
In a trial designed to try to answer Q of optimal dose of #aspirin for secondary prev. in patients with established atherosclerotic #CVD, no significant diff. found in CV events/major bleeding btwn the 81 mg & 325 mg daily doses. bit.ly/3tRJKTH#ADAPTABLE#ACC21@NEJM
Welcome to the first day of #ACC21! We are excited to hear and present a lot of great science today, including late-breaking results from @adaptablestudy and a couple of interesting panel discussions. Stay tuned! bit.ly/3goxF5q
Happening now @Collaboratory1#pctGR | Looking forward to listening to this keynote conversation and the workshop series on improving diversity in #pragmatictrials.
π£ Starting now on PCT Grand Rounds!
"Diverse Representation Among Clinical Trial Participants: Why It Is Important and How We Can Improve" with Dr. Clyde Yancy of @NUFeinbergMed.
π bit.ly/3uCLEss#pctGR
ALT NIH Collaboratory Diversity Workshop Grand Rounds: "Diverse Representation Among Clinical Trial Participants: Why It Is Important and How We Can Improve"